SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
A study reveals new insights into resistance mechanisms to hormonal therapy in breast cancer
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified
Invasive breast cancer: can surgery be eliminated after neoadjuvant systemic chemotherapy?
Phase II data report a pathologic complete response in patients who received radiotherapy after neoadjuvant therapy without surgery, when selected by image-guided vacuum-assisted core biopsy
Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer